OGN
Organon & Co. NYSE Listed May 14, 2021$13.31
Mkt Cap $3.5B
52w Low $5.69
98.3% of range
52w High $13.44
50d MA $8.14
200d MA $8.50
P/E (TTM)
18.5x
EV/EBITDA
7.9x
P/B
4.6x
Debt/Equity
11.7x
ROE
24.9%
P/FCF
3.5x
RSI (14)
—
ATR (14)
—
Beta
0.64
50d MA
$8.14
200d MA
$8.50
Avg Volume
8.6M
Organon & Co., a health care company, develops and delivers health solutions through a portfolio of prescription therapies in the United States and internationally. Its women's health portfolio comprises contraception and fertility brands, such as Nexplanon/Implanon, a long-acting reversible contraceptive. The company's biosimilars portfolio consists of three immunology products, such as Brenzys, Renflexis, and Hadlima, as well as two oncology products, including Ontruzant and Aybintio. It also offers cardiovascular products, consisting of several cholesterol-modifying medicines under the Zetia, Ezetrol, Vytorin, Inegy, Rosuzet, and Zocor brands; Cozaar and Hyzaar for the treatment of hypertension; respiratory products for various treatments to control and prevent symptoms caused by asthma under the Singulair, Dulera, Zenhale, and Asmanex brand names; and Singulair, Nasonex, Clarinex, and Aerius for treating seasonal allergic rhinitis. In addition, the company provides dermatology products under the Diprosone and Elocon brand; bone health portfolio, including Fosamax brand name; non-opioid pain management products under the Arcoxia, Diprospan, and Celestone brand names; Proscar for the treatment of symptomatic benign prostatic hyperplasia; and Propecia for the treatment of male pattern hair loss. The company sells its products primarily to drug wholesalers and retailers, hospitals, and government agencies, as well as managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions. Organon & Co. was incorporated in 2020 and is based in Jersey City, New Jersey.
30 Hudson Street · Jersey City, NJ 07302 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb 12, 2026 | BMO | 0.73 | 0.63 | -13.7% | 7.69 | -12.9% | -8.2% | -3.9% | -5.3% | -3.0% | -2.2% | — |
| Nov 10, 2025 | BMO | 0.93 | 1.01 | +8.6% | 6.78 | +2.1% | +13.7% | +10.9% | +13.7% | +12.4% | +11.1% | — |
| Aug 5, 2025 | BMO | 0.94 | 1.00 | +6.4% | 9.67 | +6.5% | -13.1% | -9.8% | -5.8% | -4.7% | -6.8% | — |
| May 1, 2025 | BMO | 0.89 | 1.02 | +14.6% | 12.93 | -21.3% | -26.9% | -25.8% | -32.6% | -29.4% | -32.3% | — |
| Feb 13, 2025 | BMO | 0.92 | 0.90 | -2.2% | 14.70 | +7.1% | +11.0% | +3.9% | +5.3% | +4.0% | +6.7% | — |
| Oct 31, 2024 | BMO | 0.90 | 0.87 | -3.3% | 17.93 | +0.4% | +4.7% | +0.8% | -5.6% | -8.2% | -11.9% | — |
| Aug 6, 2024 | BMO | 1.06 | 1.12 | +5.7% | 20.19 | -3.0% | -7.6% | -5.6% | -3.1% | -0.2% | -3.6% | — |
| May 2, 2024 | BMO | 0.97 | 1.22 | +25.8% | 18.83 | +3.2% | +3.6% | +4.1% | +9.8% | +8.3% | +8.2% | — |
| Feb 15, 2024 | BMO | 0.80 | 0.88 | +10.0% | 16.36 | +9.1% | +13.8% | +14.4% | +13.0% | +13.3% | +13.4% | — |
| Nov 2, 2023 | BMO | 1.04 | 0.87 | -16.3% | 14.65 | -1.2% | -10.5% | -9.2% | -14.3% | -15.3% | -16.2% | — |
| Aug 8, 2023 | BMO | 0.97 | 1.31 | +35.1% | 21.80 | +3.7% | +9.0% | +6.2% | +8.3% | +6.2% | +5.8% | — |
| May 4, 2023 | BMO | 1.18 | 1.08 | -8.5% | 24.24 | -2.8% | -9.2% | -7.1% | -10.0% | -12.4% | -11.3% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 29 | BNP Paribas | Downgrade | Outperform → Neutral | — | $13.32 | $13.34 | +0.2% | +0.2% | -0.5% | -0.2% | -0.5% | +0.2% |
| Apr 28 | Piper Sandler | Upgrade | Underweight → Neutral | $14 | $13.16 | $13.19 | +0.2% | +1.2% | +1.4% | +0.7% | +1.0% | +0.8% |
| Feb 24 | Barclays | Maintains | Underweight → Underweight | — | $7.92 | $7.86 | -0.8% | +2.8% | -5.2% | -8.7% | -8.0% | -9.2% |
| Nov 11 | JP Morgan | Maintains | Underweight → Underweight | — | $7.71 | $7.62 | -1.2% | -2.5% | +0.0% | -1.2% | -2.3% | -0.8% |
| Nov 11 | Morgan Stanley | Maintains | Equal Weight → Equal Weight | — | $7.71 | $7.62 | -1.2% | -2.5% | +0.0% | -1.2% | -2.3% | -0.8% |
| May 15 | Piper Sandler | Maintains | Overweight → Overweight | — | $8.04 | $8.09 | +0.6% | +9.1% | +12.4% | +11.9% | +9.0% | +4.9% |
| May 5 | Morgan Stanley | Maintains | Equal Weight → Equal Weight | — | $9.59 | $9.36 | -2.4% | -9.1% | -4.8% | -8.7% | -5.9% | -9.2% |
| Apr 9 | Morgan Stanley | Maintains | Equal Weight → Equal Weight | — | $11.65 | $11.52 | -1.1% | +8.5% | -1.9% | -4.0% | -3.0% | -5.2% |
| Feb 14 | Barclays | Maintains | Overweight → Overweight | — | $16.32 | $16.14 | -1.1% | -6.4% | -5.1% | -6.3% | -3.9% | -5.1% |
| Feb 14 | Morgan Stanley | Maintains | Equal Weight → Equal Weight | — | $16.32 | $16.14 | -1.1% | -6.4% | -5.1% | -6.3% | -3.9% | -5.1% |
| Sep 6 | JP Morgan | Downgrade | Neutral → Underweight | — | $21.36 | $20.96 | -1.9% | -4.1% | -5.5% | -5.9% | -5.6% | -5.0% |
| May 6 | Goldman Sachs | Maintains | Neutral → Neutral | — | $19.61 | $19.75 | +0.7% | +5.5% | +4.0% | +3.9% | +4.6% | +4.1% |
| May 3 | Goldman Sachs | Maintains | Neutral → Neutral | — | $19.50 | $20.00 | +2.6% | +0.6% | +6.1% | +4.6% | +4.5% | +5.2% |
| Apr 29 | Piper Sandler | Maintains | Overweight → Overweight | — | $18.55 | $18.69 | +0.8% | +1.9% | +0.3% | +1.5% | +5.1% | +5.7% |
| Feb 20 | Goldman Sachs | Maintains | Neutral → Neutral | — | $18.71 | $18.75 | +0.2% | -1.2% | -1.0% | -0.9% | -1.1% | -5.7% |
| Nov 22 | Piper Sandler | Maintains | Overweight → Overweight | — | $11.03 | $11.14 | +1.0% | +1.9% | +3.0% | +3.6% | +2.4% | +3.4% |
| Nov 3 | Goldman Sachs | Downgrade | Buy → Neutral | — | $13.11 | $13.28 | +1.3% | +1.4% | -4.2% | -5.3% | -6.4% | -12.9% |
| Oct 25 | Piper Sandler | Maintains | Overweight → Overweight | — | $15.76 | $15.55 | -1.3% | -0.7% | -2.9% | -5.1% | -5.3% | -6.2% |
| Oct 11 | Morgan Stanley | Maintains | Equal Weight → Equal Weight | — | $17.29 | $17.37 | +0.5% | -0.4% | -3.8% | +0.2% | -2.5% | -4.9% |
| Aug 9 | Morgan Stanley | Maintains | Equal Weight → Equal Weight | — | $23.77 | $23.88 | +0.5% | -2.6% | -0.7% | -2.6% | -3.0% | -2.1% |
| May 8 | Morgan Stanley | Maintains | Equal Weight → Equal Weight | — | $22.52 | $22.67 | +0.7% | -3.1% | -5.7% | -4.5% | -6.1% | -7.3% |
| Mar 16 | Raymond James | Maintains | Outperform → Outperform | — | $21.52 | $21.53 | +0.0% | +0.9% | +0.7% | +4.0% | +4.0% | +1.5% |
| Nov 4 | Morgan Stanley | Maintains | Equal Weight → Equal Weight | — | $25.88 | $25.88 | +0.0% | -5.9% | -7.3% | -9.0% | -7.8% | -4.5% |
| Oct 14 | BofA Securities | Downgrade | Neutral → Underperform | — | $24.03 | $23.22 | -3.4% | -3.0% | -0.9% | +0.6% | -1.0% | -2.0% |
| Oct 12 | Morgan Stanley | Maintains | Equal Weight → Equal Weight | — | $23.50 | $23.39 | -0.5% | +0.6% | +2.3% | -0.8% | +1.3% | +2.9% |
| Sep 6 | Piper Sandler | Upgrade | Neutral → Overweight | — | $28.50 | $28.85 | +1.2% | +0.7% | +1.6% | +3.0% | +4.7% | +4.2% |
| Aug 5 | BofA Securities | Downgrade | Buy → Neutral | — | $32.41 | $31.92 | -1.5% | -2.8% | -2.7% | -3.1% | -2.7% | -2.2% |
| Jul 8 | Morgan Stanley | Maintains | Equal Weight → Equal Weight | — | $33.05 | $32.87 | -0.5% | -0.9% | -1.1% | -0.6% | -2.3% | -3.6% |
| Apr 27 | Goldman Sachs | Maintains | Buy → Buy | — | $31.66 | $31.99 | +1.0% | +2.4% | +4.2% | +2.1% | +1.3% | +2.5% |
| Apr 6 | Morgan Stanley | Maintains | Equal Weight → Equal Weight | — | $35.40 | $35.56 | +0.5% | +2.3% | +2.3% | +1.3% | -0.6% | -1.2% |
| Feb 22 | Morgan Stanley | Maintains | Equal Weight → Equal Weight | — | $36.09 | $36.10 | +0.0% | -0.3% | -1.6% | -0.2% | +4.1% | +3.4% |
| Oct 7 | Piper Sandler | Maintains | Neutral → Neutral | — | $33.07 | $32.99 | -0.2% | -0.7% | -1.5% | +0.4% | -0.7% | +0.2% |
| Sep 1 | BofA Securities | Maintains | Buy → Buy | — | $33.89 | $34.45 | +1.7% | +2.0% | +5.1% | +5.1% | +5.2% | +3.2% |
| Aug 16 | Morgan Stanley | Maintains | Equal Weight → Equal Weight | — | $34.21 | $34.24 | +0.1% | +0.4% | +3.4% | -1.8% | -0.3% | -2.9% |
| Jul 23 | Citigroup | Maintains | Buy → Buy | — | $30.92 | $30.89 | -0.1% | -3.6% | -4.1% | -5.8% | -3.8% | -5.5% |
| Jul 22 | Citigroup | Maintains | Buy → Buy | — | $30.46 | $30.43 | -0.1% | +1.5% | -2.2% | -2.6% | -4.4% | -2.4% |
| Jun 15 | JP Morgan | Maintains | Neutral → Neutral | — | $30.28 | $30.03 | -0.8% | +5.1% | +1.4% | +3.9% | -1.0% | -2.9% |
| Date | Insider | Title | Type | Shares | Price | Value | Owned After | D1% | D5% |
|---|---|---|---|---|---|---|---|---|---|
| May 6, 2026 | Holzbaur LynetteOff | SVP and Corporate Controller | Sell | 26,448 | $13.35 | $353K | — | +0.23% | — |
| May 6, 2026 | Holzbaur LynetteOff | SVP and Corporate Controller | Buy | 26,448 | $13.35 | $353K | 52,850 | +0.23% | — |
8-K
Organon & Co. -- 8-K Filing
Organon & Co. secured committed debt financing to fund a merger's per-share consideration and refinance existing debt, with equity awards treatment specified in the merger agreement.
Apr 27
8-K · 8.01
!! High
Organon & Co. -- 8-K 8.01: Material Event / Announcement
Organon's Audit Committee completed an independent investigation into undisclosed matters, potentially resolving governance concerns and reducing litigation risk for shareholders.
Feb 20
8-K · 7.01
! Medium
Organon & Co. -- 8-K 7.01: Regulation FD Disclosure
Organon made its Q4 2025 earnings presentation available to investors, disclosing financial results for the quarter and full year ended December 31, 2025.
Feb 12
Data updated apr 26, 2026 5:06pm
· Source: massive.com